Merck (NYSE: MRK) revenue
Merck reported revenue of $65,011m for fiscal 2025, 1.3% more than in fiscal 2024 ($64,168m). Since fiscal 2016 its revenue has grown by 63.3%, an average growth of 5.6% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $65,011m | +1.3% | $22,424m | 34.5% |
| 2024 | $64,168m | +6.7% | $21,207m | 33.0% |
| 2023 | $60,115m | +1.4% | $3,035m | 5.0% |
| 2022 | $59,283m | +21.7% | $17,406m | 29.4% |
| 2021 | $48,704m | +17.3% | $14,685m | 30.2% |
| 2020 | $41,518m | +6.1% | $6,694m | 16.1% |
| 2019 | $39,121m | −7.5% | $8,064m | 20.6% |
| 2018 | $42,294m | +5.4% | $9,473m | 22.4% |
| 2017 | $40,122m | +0.8% | $7,275m | 18.1% |
| 2016 | $39,807m | — | $5,352m | 13.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Merck
- How much revenue did Merck make in fiscal 2025?
- Merck reported revenue of $65,011m for fiscal 2025, compared with $64,168m in fiscal 2024.
- How much has the revenue of Merck grown?
- Between fiscal 2016 and fiscal 2025 it went from $39,807m to $65,011m: 63.3% more, an average growth of 5.6% a year.
- What was the best year for revenue at Merck?
- Of its last 10 fiscal years, fiscal 2025, with $65,011m.
- Where do the figures for Merck come from?
- From the annual report (Form 10-K) that Merck files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Merck files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Merck: the Merck page · annual accounts · net income · dividends paid · insider transactions.
Dividend per share of Merck by fiscal year, with the filing behind every figure: Merck dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.